Balixafortide - Polyphor

Drug Profile

Balixafortide - Polyphor

Alternative Names: POL-6326

Latest Information Update: 27 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Polyphor
  • Class Antineoplastics; Cyclic peptides; Epitopes; Macrocyclic compounds; Peptidomimetics
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma; Cancer; Coronary artery restenosis; Inflammation; Stem cell mobilisation; Wounds

Highest Development Phases

  • Phase II Myocardial infarction; Stem cell mobilisation
  • Phase I Breast cancer
  • No development reported Coronary artery restenosis; Inflammation; Solid tumours; Wounds

Most Recent Events

  • 10 Sep 2018 Polyphor plans a pivotal trial (Combination therapy, Late-stage disease) for Breast Cancer
  • 06 Sep 2018 Polyphor plans a pivotal trial in the US
  • 01 Aug 2018 Polyphor completes a phase I trial in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Spain and USA (IV) (NCT01837095)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top